5471-55-6

Usage

Uses

Used in Pharmaceutical Industry:
2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE is used as a precursor in the synthesis of pharmaceutical drugs for its ability to contribute to the formation of new compounds with potential therapeutic effects.
Used in Chemical Industry:
2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE is used as a catalyst in chemical reactions, facilitating various processes due to its reactive nature and enhancing the efficiency of these reactions.
Used in Organic Synthesis:
2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE is used as a reagent in organic synthesis, playing a crucial role in the creation of complex organic molecules for a variety of applications.
Used in Neurological Research:
2-CYCLOHEXYL-ETHYLAMINE HYDROCHLORIDE has potential use in the treatment of neurological disorders, serving as a compound of interest for research and development due to its ability to interact with certain neurotransmitter receptors, which could lead to advancements in understanding and treating such conditions.

InChI:InChI=1/C8H17N.ClH/c9-7-6-8-4-2-1-3-5-8;/h8H,1-7,9H2;1H

Upstream product

• 64-04-0 phenethylamine 
• 4442-79-9 cyclohexylethan-1-ol 
• 931-48-6 2-cyclohexylacetylene 
• 3399-73-3 2-(1-cyclohexenyl)ethylamine 
• 41763-92-2 2-(2-cyclohexylethyl)isoindoline-1,3-dione 

Downstream Products

• 902527-35-9 3-chloro-6-[4-chloro-3-[[(2-cyclohexylethyl)amino]carbonyl]phenyl]-2-pyridinecarboxylic acid methyl ester 
• 902527-27-9 5-chloro-2-[4-chloro-3-[[(2-cyclohexylethyl)amino]carbonyl]phenyl]-3-pyridinecarboxylic acid methyl ester 
• 454646-66-3 3-(1H-imidazol-4-yl)propyl 2-cyclohexylethylcarbamate hydrogen maleate 
• 76649-96-2 c-hexylethyl isocyanate 
• 803736-98-3 C₁₈H₂₁ClN₂O₂ 
• 1392490-96-8 N-[1-({4-[(2-cyclohexylethyl)carbamoyl]benzene}sulfonyl)piperidin-4-yl]carbamic acid tert-butyl ester 
• 1132803-45-2 N-(2-cyclohexylethyl)-2-(2-(phenylsulfonyl)ethylthio)-nicotinamide 
• 864274-50-0 3-[(2-cyclohexylethyl)amino]-4-nitrobenzonitrile 

Relevant academic research and scientific papers

ANTIVIRAL COMPOUNDS AND USE THEREOF

The present invention relates to compounds of formula (I), their use as medicaments, in particular as broad spectrum antiviral agents, their combination with a further antiviral agent and relative pharmaceutical compositions. In particular, the compounds of the invention are useful in the treatment of a disease caused by an enveloped virus.

Regio- and stereoselective hydroamination of alkynes using an ammonia surrogate: Synthesis of N -Silylenamines as reactive synthons

An anti-Markovnikov selective hydroamination of alkynes with N-silylamines to afford N-silylenamines is reported. The reaction is catalyzed by a bis(amidate)bis(amido)Ti(IV) catalyst and is compatible with a variety of terminal and internal alkynes. Stoichiometric mechanistic studies were also performed. This method easily affords interesting N-silylenamine synthons in good to excellent yields and the easily removable silyl protecting group enables the catalytic synthesis of primary amines.

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands

Previous studies have shown that several imidazole derivatives posses affinity to histamine H3 and H4 receptors. Continuing our study on structural requirements responsible for affinity and selectivity for H3/H4 receptor subtypes, two series of 3-(1H-imidazol-4-yl)propyl carbamates were prepared: a series of unsaturated alkyl derivatives (1-9) and a series possessing a cycloalkyl group different distances to the carbamate moiety (10-13). The compounds were tested for their affinities at the human histamine H3 receptor, stably expressed in CHO-K1 cells. Compounds 1, 2, 5-7, 10-13 were investigated for their affinities at the human histamine H4 receptor co-expressed with Gαi2 and Gβ1γ2 subunits in Sf9 cells. To expand the pharmacological profile, compounds were further tested for their H3 receptor antagonist activity on guinea pig ileum and in vivo after oral administration to mice. All tested compounds exhibited good affinity for the human histamine H3 receptor with Ki values in the range from 14 to 194 nM. All compounds were active in vivo after peroral administration (p.o.) to Swiss mice, thus demonstrating their ability to cross the blood-brain barrier. The most potent H3 receptor ligand of these series was compound 5, 3-(1H-imidazol-4-yl)propyl pent-4-enylcarbamate with the highest affinity (Ki = 14 nM). Additionally, compound 3 showed remarkable central nervous system (CNS) H3R activity, increasing the Nτ-methylhistamine levels in mice with an ED 50 value of 0.55 mg/kg, p.o. evidencing therefore, a twofold increase of inverse agonist/antagonist potency compared to the reference inverse agonist/antagonist thioperamide. In this study, the imidazole propyloxy carbamate moiety was kept constant. The different lipophilic moieties connected to the carbamate functionality in the eastern part of the molecule had a range of influences on the human H4 receptor affinity (154-1326 nM).

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES

This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias and in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.

THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, ne